MINGSIGHT PHARMACEUTICALS INC has a total of 30 patent applications. It decreased the IP activity by 57.0%. Its first patent ever was published in 2015. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are NAUREX INC, FIBROGEN INC and BIOAXONE THERAPEUTIQUE INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | Australia | 3 | |
#5 | Canada | 3 | |
#6 | China | 3 | |
#7 | Republic of Korea | 2 | |
#8 | Singapore | 2 | |
#9 | Taiwan | 2 | |
#10 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds | |
#4 | Peptides | |
#5 | Organic chemistry methods |
# | Name | Total Patents |
---|---|---|
#1 | Zhang Kai | 27 |
#2 | Niesman Michael | 26 |
#3 | Northen Julian | 3 |
#4 | Olmstead Kay | 3 |
#5 | Michael Niesman | 1 |
Publication | Filing date | Title |
---|---|---|
US2021069194A1 | Combination therapy for the treatment of cancer | |
WO2018218205A1 | Pkc inhibitor solid state forms | |
CN109715166A | The treatment of cancer | |
AU2016355303A1 | Treatment of autoimmune disease | |
CN105377852A | Treatment of autoimmune disease |